IFRX:NSD-InflaRx N.V. (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.57

Change

0.00 (0.00)%

Market Cap

USD 0.09B

Volume

0.05M

Analyst Target

USD 9.28
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 35.29B
ARGX argenx NV ADR

N/A

USD 32.06B
MRNA Moderna Inc

N/A

USD 25.25B
BGNE BeiGene Ltd

N/A

USD 24.38B
RPRX Royalty Pharma Plc

N/A

USD 16.72B
UTHR United Therapeutics Corporatio..

N/A

USD 15.71B
SMMT Summit Therapeutics PLC

N/A

USD 15.35B
PCVX Vaxcyte Inc

N/A

USD 14.00B

ETFs Containing IFRX

VSS Vanguard FTSE All-World e.. 0.34 % 0.12 %

N/A

USD 8.96B
ENY 0.00 % 0.66 %

N/A

N/A
FQC:CA 0.00 % 1.01 %

N/A

N/A
HEE:CA 0.00 % 0.84 %

N/A

N/A
SCHC Schwab International Smal.. 0.00 % 0.12 %

N/A

N/A
XEG:CA iShares S&P/TSX Capped En.. 0.00 % 0.61 %

N/A

CAD 1.40B
XMD:CA iShares S&P/TSX Completio.. 0.00 % 0.61 %

N/A

CAD 0.22B
ZEO:CA BMO Equal Weight Oil & Ga.. 0.00 % 0.61 %

N/A

CAD 0.21B
ZJO:CA 0.00 % 0.60 %

N/A

N/A
BREA:CA Brompton Sustainable Real.. 0.00 % 0.00 %

N/A

CAD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.68% 38% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.68% 38% F 38% F
Trailing 12 Months  
Capital Gain -47.32% 17% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.32% 17% F 16% F
Trailing 5 Years  
Capital Gain -36.44% 36% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.44% 36% F 30% F
Average Annual (5 Year Horizon)  
Capital Gain -3.16% N/A N/A 35% F
Dividend Return -3.16% N/A N/A 32% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 74.55% N/A N/A 24% F
Risk Adjusted Return -4.24% N/A N/A 36% F
Market Capitalization 0.09B 45% F 36% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.